Introduction of everolimus in kidney transplant recipients at a late posttransplant stage

Table 3 Pros and cons of late conversion to everolimus with calcineurin inhibitor elimination or minimization in kidney transplant recipients

Advantage	Disadvantage
Due to EVL introduction Antitumoral effect (especially on nonmelanoma skin carcinoma) Antiviral effect (especially on CMV and BKV infection) Antiproliferative effect Antiatherosclerotic effect	Due to EVL introduction Adverse events (gastrointestinal disorders, hyperlipidemia, interstitial pneumonitis, edema, mouth ulcers, proteinuria, impaired wound healing, hematotoxicity and so on)
Due to CNI elimination or minimization Favorable graft function	Due to CNI elimination or minimization Risk of de novo DSA

BKV: BK virus; CMV: Cytomegalovirus; CNI: Calcineurin inhibitor; DSA: Donor-specific HLA antibodies; EVL: Everolimus.